NF-κB in type 1 diabetes

Inflammation and Allergy - Drug Targets

Volumn 10, Issue 3, 2011, Pages 208-217

  Zhao, Yuxing ^a   Krishnamurthy, Balasubramanian ^a   Mollah, Zia U A ^b   Kay, Thomas W H ^b   Thomas, Helen E ^a  

^a ST VINCENT'S INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

NF B; Pancreatic beta cells; Type 1 diabetes

Indexed keywords

AUTOANTIBODY; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; TUMOR NECROSIS FACTOR ALPHA;

ANTIGEN PRESENTATION; APOPTOSIS; ARTICLE; CELL SURVIVAL; CYTOKINE RELEASE; DENDRITIC CELL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MONOCYTE; NONHUMAN; PANCREAS ISLET BETA CELL; PANCREAS ISLET TRANSPLANTATION; PATHOGENESIS; PROTEIN FUNCTION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

EID: 79958200223     PISSN: 18715281     EISSN: 18715281     Source Type: Journal    
DOI: 10.2174/187152811795564046     Document Type: Article

References (86)

1. Kumar, A.; Takada, Y.; Boriek, A. M.; Aggarwal, B. B. Nuclear factor-kappaB: its role in health and disease. J. Mol. Med., 2004, 82(7), 434-448.
2. Barker, J. M.; McFann, K.; Harrison, L. C.; Fourlanos, S.; Krischer, J.; Cuthbertson, D.; Chase, H. P.; Eisenbarth, G. S. Pretype 1 diabetes dysmetabolism: maximal sensitivity achieved with both oral and intravenous glucose tolerance testing. J. Pediatr., 2007, 150(1), 31-36 e6.
3. Sosenko, J. M.; Palmer, J. P.; Greenbaum, C. J.; Mahon, J.; Cowie, C.; Krischer, J. P.; Chase, H. P.; White, N. H.; Buckingham, B.; Herold, K. C.; Cuthbertson, D.; Skyler, J. S. Patterns of metabolic progression to type 1 diabetes in the Diabetes Prevention Trial-Type 1. Diabetes Care, 2006, 29(3), 643-649.
4. Stene, L. C.; Barriga, K.; Hoffman, M.; Kean, J.; Klingensmith, G.; Norris, J. M.; Erlich, H. A.; Eisenbarth, G. S.; Rewers, M. Normal but increasing hemoglobin A1c levels predict progression from islet autoimmunity to overt type 1 diabetes: Diabetes Autoimmunity Study in the Young (DAISY). Pediatr. Diabetes, 2006, 7(5), 247-253.
5. Patterson, C. C.; Dahlquist, G. G.; Gyurus, E.; Green, A.; Soltesz, G. Incidence trends for childhood type 1 diabetes in Europe during 1989-2003 and predicted new cases 2005-20: a multicentre prospective registration study. Lancet, 2009, 373(9680), 2027-2033.
6. Dabelea, D. The accelerating epidemic of childhood diabetes. Lancet, 2009, 373(9680), 1999-2000.
7. Onkamo, P.; Vaananen, S.; Karvonen, M.; Tuomilehto, J. Worldwide increase in incidence of Type I diabetes--the analysis of the data on published incidence trends. Diabetologia, 1999, 42(12), 1395-1403.
8. Vehik, K.; Hamman, R. F.; Lezotte, D.; Norris, J. M.; Klingensmith, G.; Bloch, C.; Rewers, M.; Dabelea, D. Increasing incidence of type 1 diabetes in 0- to 17-year-old Colorado youth. Diabetes Care, 2007, 30(3), 503-509.
9. Chistiakov, D. A.; Voronova, N. V.; Chistiakova, E. I. Identification of new susceptibility genes for type 1 diabetes: an update. Curr. Immunol. Rev., 2008, 4(3), 116-133.
10. Concannon, P.; Erlich, H. A.; Julier, C.; Morahan, G.; Nerup, J.; Pociot, F.; Todd, J. A.; Rich, S. S. Type 1 diabetes: evidence for susceptibility loci from four genome-wide linkage scans in 1,435 multiplex families. Diabetes, 2005, 54(10), 2995-3001.
11. Eizirik, D. L.; Moore, F.; Flamez, D.; Ortis, F. Use of a systems biology approach to understand pancreatic beta-cell death in Type 1 diabetes. Biochem. Soc. Trans., 2008, 36(Pt 3), 321-327.
12. She, J. X. Susceptibility to type I diabetes: HLA-DQ and DR revisited. Immunol. Today, 1996, 17(7), 323-329.
13. Noble, J. A.; Valdes, A. M.; Bugawan, T. L.; Apple, R. J.; Thomson, G.; Erlich, H. A. The HLA class I A locus affects susceptibility to type 1 diabetes. Hum. Immunol., 2002, 63(8), 657-664.
14. Pugliese, A.; Zeller, M.; Fernandez, A., Jr.; Zalcberg, L. J.; Bartlett, R. J.; Ricordi, C.; Pietropaolo, M.; Eisenbarth, G. S.; Bennett, S. T.; Patel, D. D. The insulin gene is transcribed in the human thymus and transcription levels correlated with allelic variation at the INS VNTR-IDDM2 susceptibility locus for type 1 diabetes. Nat. Genet., 1997, 15(3), 293-297.
15. Spielman, R. S.; McGinnis, R. E.; Ewens, W. J. Transmission test for linkage disequilibrium: the insulin gene region and insulindependent diabetes mellitus (IDDM). Am J. Hum. Genet, 1993, 52(3), 506-516.
16. Bottini, N.; Musumeci, L.; Alonso, A.; Rahmouni, S.; Nika, K.; Rostamkhani, M.; MacMurray, J.; Meloni, G. F.; Lucarelli, P.; Pellecchia, M.; Eisenbarth, G. S.; Comings, D.; Mustelin, T. A functional variant of lymphoid tyrosine phosphatase is associated with type I diabetes. Nat. Genet, 2004, 36(4), 337-338.
17. Zheng, W.; She, J. X. Genetic association between a lymphoid tyrosine phosphatase (PTPN22) and type 1 diabetes. Diabetes, 2005, 54(3), 906-908.
18. Hegazy, D. M.; O'Reilly, D. A.; Yang, B. M.; Hodgkinson, A. D.; Millward, B. A.; Demaine, A. G. NFkappaB polymorphisms and susceptibility to type 1 diabetes. Genes Immun., 2001, 2(6), 304-308.
19. Onengut-Gumuscu, S.; Concannon, P. Mapping genes for autoimmunity in humans: type 1 diabetes as a model. Immunol. Rev., 2002, 190, 182-194.
20. Rewers, M.; Zimmet, P. The rising tide of childhood type 1 diabetes--what is the elusive environmental trigger? Lancet, 2004, 364(9446), 1645-1647.
21. Wentworth, J. M.; Fourlanos, S.; Harrison, L. C. Reappraising the stereotypes of diabetes in the modern diabetogenic environment. Nat. Rev. Endocrinol., 2009, 5(9), 483-489.
22. Wen, L.; Ley, R. E.; Volchkov, P. Y.; Stranges, P. B.; Avanesyan, L.; Stonebraker, A. C.; Hu, C.; Wong, F. S.; Szot, G. L.; Bluestone, J. A.; Gordon, J. I.; Chervonsky, A. V. Innate immunity and intestinal microbiota in the development of Type 1 diabetes. Nature, 2008, 455(7216), 1109-1113.
23. Verge, C. F.; Gianani, R.; Kawasaki, E.; Yu, L.; Pietropaolo, M.; Jackson, R. A.; Chase, H. P.; Eisenbarth, G. S. Prediction of type I diabetes in first-degree relatives using a combination of insulin, GAD, and ICA512bdc/IA-2 autoantibodies. Diabetes, 1996, 45(7), 926-933.
24. Wenzlau, J. M.; Juhl, K.; Yu, L.; Moua, O.; Sarkar, S. A.; Gottlieb, P.; Rewers, M.; Eisenbarth, G. S.; Jensen, J.; Davidson, H. W.; Hutton, J. C. The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes. Proc. Natl. Acad. Sci. USA, 2007, 104(43), 17040-1705.
25. Krishnamurthy, B.; Dudek, N. L.; McKenzie, M. D.; Purcell, A. W.; Brooks, A. G.; Gellert, S.; Colman, P. G.; Harrison, L. C.; Lew, A. M.; Thomas, H. E.; Kay, T. W. Responses against islet antigens in NOD mice are prevented by tolerance to proinsulin but not IGRP. J. Clin. Invest., 2006, 116(12), 3258-3265.
26. Nakayama, M.; Abiru, N.; Moriyama, H.; Babaya, N.; Liu, E.; Miao, D.; Yu, L.; Wegmann, D. R.; Hutton, J. C.; Elliott, J. F.; Eisenbarth, G. S. Prime role for an insulin epitope in the development of type 1 diabetes in NOD mice. Nature, 2005, 435(7039), 220-223.
27. Tsai, S.; Shameli, A.; Santamaria, P. CD8+ T cells in type 1 diabetes. Adv. Immunol., 2008, 100, 79-124.
28. Hayashi, T.; Faustman, D. NOD mice are defective in proteasome production and activation of NF-kappaB. Mol. Cell Biol., 1999, 19(12), 8646-8659.
29. Kessler, B. M.; Lennon-Dumenil, A. M.; Shinohara, M. L.; Lipes, M. A.; Ploegh, H. L. LMP2 expression and proteasome activity in NOD mice. Nat. Med., 2000, 6(10), 1064; author reply 1065-1066.
30. Runnels, H. A.; Watkins, W. A.; Monaco, J. J. LMP2 expression and proteasome activity in NOD mice. Nat. Med., 2000, 6(10), 1064-1065; author reply 1065-1066.
31. Lamhamedi-Cherradi, S. E.; Zheng, S.; Hilliard, B. A.; Xu, L.; Sun, J.; Alsheadat, S.; Liou, H. C.; Chen, Y. H. Transcriptional regulation of type I diabetes by NF-kappa B. J. Immunol., 2003, 171(9), 4886-4892.
32. Like, A. A.; Rossini, A. A. Streptozotocin-induced pancreatic insulitis: new model of diabetes mellitus. Science, 1976, 193(4251), 415-417.
33. Katz, J. D.; Benoist, C.; Mathis, D. T helper cell subsets in insulindependent diabetes. Science, 1995, 268(5214), 1185-1188.
34. Weaver, D. J., Jr.; Poligone, B.; Bui, T.; Abdel-Motal, U. M.; Baldwin, A. S., Jr.; Tisch, R. Dendritic cells from nonobese diabetic mice exhibit a defect in NF-kappa B regulation due to a hyperactive I kappa B kinase. J. Immunol., 2001, 167(3), 1461-1468.
35. Poligone, B.; Weaver, D. J., Jr.; Sen, P.; Baldwin, A. S., Jr.; Tisch, R. Elevated NF-kappaB activation in nonobese diabetic mouse dendritic cells results in enhanced APC function. J. Immunol., 2002, 168(1), 188-196.
36. Wheat, W.; Kupfer, R.; Gutches, D. G.; Rayat, G. R.; Beilke, J.; Scheinman, R. I.; Wegmann, D. R. Increased NF-kappa B activity in B cells and bone marrow-derived dendritic cells from NOD mice. Eur. J. Immunol., 2004, 34(5), 1395-404.
37. Liu, J.; Beller, D. Aberrant production of IL-12 by macrophages from several autoimmune-prone mouse strains is characterized by intrinsic and unique patterns of NF-kappa B expression and binding to the IL-12 p40 promoter. J. Immunol., 2002, 169(1), 581-586.
38. Liu, J.; Beller, D. I. Distinct pathways for NF-kappa B regulation are associated with aberrant macrophage IL-12 production in lupusand diabetes-prone mouse strains. J. Immunol., 2003, 170(9), 4489-4496.
39. Sen, P.; Bhattacharyya, S.; Wallet, M.; Wong, C. P.; Poligone, B.; Sen, M.; Baldwin, A. S., Jr.; Tisch, R. NF-kappa B hyperactivation has differential effects on the APC function of nonobese diabetic mouse macrophages. J. Immunol., 2003, 170(4), 1770-1780.
40. Stoffels, K.; Overbergh, L.; Giulietti, A.; Kasran, A.; Bouillon, R.; Gysemans, C.; Mathieu, C. NOD macrophages produce high levels of inflammatory cytokines upon encounter of apoptotic or necrotic cells. J. Autoimmun., 2004, 23(1), 9-15.
41. Ma, L.; Qian, S.; Liang, X.; Wang, L.; Woodward, J. E.; Giannoukakis, N.; Robbins, P. D.; Bertera, S.; Trucco, M.; Fung, J. J.; Lu, L. Prevention of diabetes in NOD mice by administration of dendritic cells deficient in nuclear transcription factor-kappaB activity. Diabetes, 2003, 52(8), 1976-1985.
42. Mollah, Z. U.; Pai, S.; Moore, C.; O'Sullivan, B. J.; Harrison, M. J.; Peng, J.; Phillips, K.; Prins, J. B.; Cardinal, J.; Thomas, R. Abnormal NF-kappa B function characterizes human type 1 diabetes dendritic cells and monocytes. J. Immunol., 2008, 180(5), 3166-3175.
43. Takahashi, K.; Honeyman, M. C.; Harrison, L. C. Impaired yield, phenotype, and function of monocyte-derived dendritic cells in humans at risk for insulin-dependent diabetes. J. Immunol., 1998, 161(5), 2629-2635.
44. Pai, S.; Thomas, R. Immune deficiency or hyperactivity-Nf-kappab illuminates autoimmunity. J. Autoimmun., 2008, 31(3), 245-251.
45. Wehrwein, G.; Neumeier, M.; Schaffler, A.; Kopp, A.; Weigert, J.; Abke, S.; Scholmerich, J.; Buechler, C. Lipopolysaccharide regulated protein expression is only partly impaired in monocytes from patients with type I diabetes. Cardiovasc. Diabetol., 2006, 5, 5.
46. Kutlu, B.; Darville, M. I.; Cardozo, A. K.; Eizirik, D. L. Molecular regulation of monocyte chemoattractant protein-1 expression in pancreatic beta-cells. Diabetes, 2003, 52(2), 348-355.
47. McInerney, M. F.; Alexander, L. A.; Morran, M. P.; Pietropaolo, M. Innate immunity, toll-like receptors, and diabetes. Curr. Immunol. Rev., 2009, 5(2), 111-121.
48. Liu, D.; Cardozo, A. K.; Darville, M. I.; Eizirik, D. L. Doublestranded RNA cooperates with interferon-gamma and IL-1 beta to induce both chemokine expression and nuclear factor-kappa Bdependent apoptosis in pancreatic beta-cells: potential mechanisms for viral-induced insulitis and beta-cell death in type 1 diabetes mellitus. Endocrinology, 2002, 143(4), 1225-1234.
49. Liu, D.; Darville, M.; Eizirik, D. L. Double-stranded ribonucleic acid (RNA) induces beta-cell Fas messenger RNA expression and increases cytokine-induced beta-cell apoptosis. Endocrinology, 2001, 142(6), 2593-2599.
50. Cardozo, A. K.; Heimberg, H.; Heremans, Y.; Leeman, R.; Kutlu, B.; Kruhoffer, M.; Orntoft, T.; Eizirik, D. L. A comprehensive analysis of cytokine-induced and nuclear factor-kappa B-dependent genes in primary rat pancreatic beta-cells. J. Biol. Chem., 2001, 276(52), 48879-48886.
51. Cameron, M. J.; Arreaza, G. A.; Grattan, M.; Meagher, C.; Sharif, S.; Burdick, M. D.; Strieter, R. M.; Cook, D. N.; Delovitch, T. L. Differential expression of CC chemokines and the CCR5 receptor in the pancreas is associated with progression to type I diabetes. J. Immunol., 2000, 165(2), 1102-1110.
52. Morimoto, J.; Yoneyama, H.; Shimada, A.; Shigihara, T.; Yamada, S.; Oikawa, Y.; Matsushima, K.; Saruta, T.; Narumi, S. CXC chemokine ligand 10 neutralization suppresses the occurrence of diabetes in nonobese diabetic mice through enhanced beta cell proliferation without affecting insulitis. J. Immunol., 2004, 173(11), 7017-7024.
53. Cnop, M.; Welsh, N.; Jonas, J. C.; Jorns, A.; Lenzen, S.; Eizirik, D. L. Mechanisms of pancreatic beta-cell death in type 1 and type 2 diabetes: many differences, few similarities. Diabetes, 2005, 54(Suppl 2), S97-107.
54. Eizirik, D. L.; Mandrup-Poulsen, T. A choice of death--the signaltransduction of immune-mediated beta-cell apoptosis. Diabetologia, 2001, 44(12), 2115-2133.
55. Chang, I.; Kim, S.; Kim, J. Y.; Cho, N.; Kim, Y. H.; Kim, H. S.; Lee, M. K.; Kim, K. W.; Lee, M. S. Nuclear factor kappaB protects pancreatic beta-cells from tumor necrosis factor-alpha-mediated apoptosis. Diabetes, 2003, 52(5), 1169-1175.
56. Thomas, H. E.; Angstetra, E.; Fernandes, R. V.; Mariana, L.; Irawaty, W.; Jamieson, E. L.; Dudek, N. L.; Kay, T. W. Perturbations in nuclear factor-kappaB or c-Jun N-terminal kinase pathways in pancreatic beta cells confer susceptibility to cytokineinduced cell death. Immunol. Cell Biol., 2006, 84(1), 20-27.
57. Grey, S. T.; Arvelo, M. B.; Hasenkamp, W.; Bach, F. H.; Ferran, C. A20 inhibits cytokine-induced apoptosis and nuclear factor kappaB-dependent gene activation in islets. J. Exp. Med., 1999, 190(8), 1135-1146.
58. Liuwantara, D.; Elliot, M.; Smith, M. W.; Yam, A. O.; Walters, S. N.; Marino, E.; McShea, A.; Grey, S. T. Nuclear factor-kappaB regulates beta-cell death: a critical role for A20 in beta-cell protection. Diabetes, 2006, 55(9), 2491-2501.
59. Wajant, H.; Pfizenmaier, K.; Scheurich, P. Tumor necrosis factor signaling. Cell Death Differ., 2003, 10(1), 45-65.
60. Gyrd-Hansen, M.; Darding, M.; Miasari, M.; Santoro, M. M.; Zender, L.; Xue, W.; Tenev, T.; da Fonseca, P. C.; Zvelebil, M.; Bujnicki, J. M.; Lowe, S.; Silke, J.; Meier, P. IAPs contain an evolutionarily conserved ubiquitin-binding domain that regulates NF-kappaB as well as cell survival and oncogenesis. Nat. Cell Biol., 2008, 10(11), 1309-1317.
61. Kim, H. S.; Kim, S.; Lee, M. S. IFN-gamma sensitizes MIN6N8 insulinoma cells to TNF-alpha-induced apoptosis by inhibiting NFkappaB-mediated XIAP upregulation. Biochem. Biophys. Res. Commun., 2005, 336(3), 847-853.
62. Giannoukakis, N.; Rudert, W. A.; Trucco, M.; Robbins, P. D. Protection of human islets from the effects of interleukin-1beta by adenoviral gene transfer of an Ikappa B repressor. J. Biol. Chem., 2000, 275(47), 36509-36513.
63. Heimberg, H.; Heremans, Y.; Jobin, C.; Leemans, R.; Cardozo, A. K.; Darville, M.; Eizirik, D. L. Inhibition of cytokine-induced NFkappaB activation by adenovirus-mediated expression of a NFkappaB super-repressor prevents beta-cell apoptosis. Diabetes, 2001, 50(10), 2219-2224.
64. Akerfeldt, M. C.; Howes, J.; Chan, J. Y.; Stevens, V. A.; Boubenna, N.; McGuire, H. M.; King, C.; Biden, T. J.; Laybutt, D. R. Cytokine-induced beta-cell death is independent of endoplasmic reticulum stress signaling. Diabetes, 2008, 57(11), 3034-3044.
65. Chambers, K. T.; Unverferth, J. A.; Weber, S. M.; Wek, R. C.; Urano, F.; Corbett, J. A. The role of nitric oxide and the unfolded protein response in cytokine-induced beta-cell death. Diabetes, 2008, 57(1), 124-132.
66. Oyadomari, S.; Takeda, K.; Takiguchi, M.; Gotoh, T.; Matsumoto, M.; Wada, I.; Akira, S.; Araki, E.; Mori, M. Nitric oxide-induced apoptosis in pancreatic beta cells is mediated by the endoplasmic reticulum stress pathway. Proc. Natl. Acad. Sci. USA, 2001, 98(19), 10845-10850.
67. Tonnesen, M. F.; Grunnet, L. G.; Friberg, J.; Cardozo, A. K.; Billestrup, N.; Eizirik, D. L.; Storling, J.; Mandrup-Poulsen, T. Inhibition of nuclear factor-kappaB or Bax prevents endoplasmic reticulum stress- but not nitric oxide-mediated apoptosis in INS-1E cells. Endocrinology, 2009, 150(9), 4094-4103.
68. Darville, M. I.; Eizirik, D. L. Cytokine induction of Fas gene expression in insulin-producing cells requires the transcription factors NF-kappaB and C/EBP. Diabetes, 2001, 50(8), 1741-178.
69. McKenzie, M. D.; Carrington, E. M.; Kaufmann, T.; Strasser, A.; Huang, D. C.; Kay, T. W.; Allison, J.; Thomas, H. E. Proapoptotic BH3-only protein Bid is essential for death receptor-induced apoptosis of pancreatic beta-cells. Diabetes, 2008, 57(5), 1284-1292.
70. Hartman, M. G.; Lu, D.; Kim, M. L.; Kociba, G. J.; Shukri, T.; Buteau, J.; Wang, X.; Frankel, W. L.; Guttridge, D.; Prentki, M.; Grey, S. T.; Ron, D.; Hai, T. Role for activating transcription factor 3 in stress-induced beta-cell apoptosis. Mol. Cell. Biol., 2004, 24(13), 5721-5732.
71. Perkins, N. D. Post-translational modifications regulating the activity and function of the nuclear factor kappa B pathway. Oncogene, 2006, 25(51), 6717-6730.
72. Lee, J. H.; Song, M. Y.; Song, E. K.; Kim, E. K.; Moon, W. S.; Han, M. K.; Park, J. W.; Kwon, K. B.; Park, B. H. Overexpression of SIRT1 protects pancreatic beta-cells against cytokine toxicity by suppressing the nuclear factor-kappaB signaling pathway. Diabetes, 2009, 58(2), 344-351.
73. Larsen, L.; Storling, J.; Darville, M.; Eizirik, D. L.; Bonny, C.; Billestrup, N.; Mandrup-Poulsen, T. Extracellular signal-regulated kinase is essential for interleukin-1-induced and nuclear factor kappaB-mediated gene expression in insulin-producing INS-1E cells. Diabetologia, 2005, 48(12), 2582-2590.
74. Melloul, D. Role of NF-kappaB in beta-cell death. Biochem. Soc. Trans., 2008, 36(Pt 3), 334-339.
75. Hammar, E. B.; Irminger, J. C.; Rickenbach, K.; Parnaud, G.; Ribaux, P.; Bosco, D.; Rouiller, D. G.; Halban, P. A. Activation of NF-kappaB by extracellular matrix is involved in spreading and glucose-stimulated insulin secretion of pancreatic beta cells.J. Biol. Chem., 2005, 280(34), 30630-30637.
76. Kim, S.; Millet, I.; Kim, H. S.; Kim, J. Y.; Han, M. S.; Lee, M. K.; Kim, K. W.; Sherwin, R. S.; Karin, M.; Lee, M. S. NF-kappa B prevents beta cell death and autoimmune diabetes in NOD mice. Proc. Natl. Acad. Sci. USA, 2007, 104(6), 1913-1918.
77. Eldor, R.; Yeffet, A.; Baum, K.; Doviner, V.; Amar, D.; Ben-Neriah, Y.; Christofori, G.; Peled, A.; Carel, J. C.; Boitard, C.; Klein, T.; Serup, P.; Eizirik, D. L.; Melloul, D. Conditional and specific NF-kappaB blockade protects pancreatic beta cells from diabetogenic agents. Proc. Natl. Acad. Sci. USA, 2006, 103(13), 5072-5077.
78. Callewaert, H. I.; Gysemans, C. A.; Ladriere, L.; D'Hertog, W.; Hagenbrock, J.; Overbergh, L.; Eizirik, D. L.; Mathieu, C. Deletion of STAT-1 pancreatic islets protects against streptozotocin-induced diabetes and early graft failure but not against late rejection. Diabetes, 2007, 56(8), 2169-2173.
79. Sandberg, J. O.; Andersson, A.; Eizirik, D. L.; Sandler, S. Interleukin-1 receptor antagonist prevents low dose streptozotocin induced diabetes in mice. Biochem. Biophys. Res. Commun., 1994, 202(1), 543-548.
80. Herold, K. C.; Hagopian, W.; Auger, J. A.; Poumian-Ruiz, E.; Taylor, L.; Donaldson, D.; Gitelman, S. E.; Harlan, D. M.; Xu, D.; Zivin, R. A.; Bluestone, J. A. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N. Engl. J. Med., 2002, 346(22), 1692-1698.
81. Kaufman, A.; Herold, K. C. Anti-CD3 mAbs for treatment of type 1 diabetes. Diabetes Metab. Res. Rev., 2009, 25(4), 302-306.
82. Keymeulen, B.; Vandemeulebroucke, E.; Ziegler, A. G.; Mathieu, C.; Kaufman, L.; Hale, G.; Gorus, F.; Goldman, M.; Walter, M.; Candon, S.; Schandene, L.; Crenier, L.; De Block, C.; Seigneurin, J. M.; De Pauw, P.; Pierard, D.; Weets, I.; Rebello, P.; Bird, P.; Berrie, E.; Frewin, M.; Waldmann, H.; Bach, J. F.; Pipeleers, D.; Chatenoud, L. Insulin needs after CD3-antibody therapy in newonset type 1 diabetes. N. Engl. J. Med., 2005, 352(25), 2598-2608.
83. Bacher, S.; Schmitz, M. L. The NF-kappaB pathway as a potential target for autoimmune disease therapy. Curr. Pharm. Des., 2004, 10(23), 2827-2837.
84. Ludvigsson, J.; Faresjo, M.; Hjorth, M.; Axelsson, S.; Cheramy, M.; Pihl, M.; Vaarala, O.; Forsander, G.; Ivarsson, S.; Johansson, C.; Lindh, A.; Nilsson, N. O.; Aman, J.; Ortqvist, E.; Zerhouni, P.; Casas, R. GAD treatment and insulin secretion in recent-onset type 1 diabetes. N. Engl. J. Med., 2008, 359(18), 1909-1920.
85. Bottero, V.; Withoff, S.; Verma, I. M. NF-kappaB and the regulation of hematopoiesis. Cell Death Differ., 2006, 13(5), 785-797.
86. Gu, X. Y.; Zhou, L. F.; Zhang, M. S.; Dai, W. J.; Chen, S. Y.; He, S. H.; Ji, X. H.; Yin, K. S. Targeted NF-kappaB inhibition of asthmatic serum-mediated human monocyte-derived dendritic cell differentiation in a transendothelial trafficking model. Cell Immunol., 2009, 260(1), 14-20.